INTRODUCTION
We recently reported (1) a new approach to the synthesis of oligodeoxyribonucleotides in solution. This approach, which is based on H-phosphonate coupling (2) , is indicated in outline in Scheme 1. Coupling between a protected nucleoside or oligonucleotide 3′-H-phosphonate 1 and a protected nucleoside or oligonucleotide with a free 5′-hydroxy function 2 is effected rapidly by treatment with di-(2-chlorophenyl) phosphorochloridate 5 (1) in pyridine/dichloromethane solution at -40_C. The resulting H-phosphonate diester is not isolated but is immediately allowed to react with 2-(4-chlorophenyl)sulphanyl-1H-isoindole-1,3(2H)-dione 6a (3) , also at -40_C, to give the fully protected dinucleoside phosphorothioate 3. Side reactions are not observed and the isolated yields of products are virtually quantitative. In the first unblocking step (step iii), S-(4-chlorophenyl) phosphorothioate triester linkages (as in 3) are quantitatively converted into the corresponding phosphodiester internucleotide linkages (as in 4) by treatment (4) with E-2-nitrobenzaldoxime 7 and N 1 ,N 1 ,N 3 ,N 3 -tetramethylguanidine (TMG) 8 in acetonitrile solution. Subsequent unblocking steps depend on the other protecting groups that are used. We believe that this methodology is potentially suitable for the synthesis of really large (say multikilogram) quantities of oligonucleotides. We now report the results of some preliminary studies directed towards the solution phase synthesis of linear and cyclic oligoribonucleotides involving this H-phosphonate-based methodology.
The main building blocks required in this study were triethylammonium salts of 5′-O-(DMTr)-2′-O-(Fpmp)-ribonucleoside-3′-H-phosphonates 10 in which the adenine, cytosine and guanine base residues were protected as in 12, 13 and 14, respectively. These building blocks were prepared in very high (96-98%) yields from the corresponding nucleoside building blocks 9 by the procedure (5) indicated (Scheme 2a and Materials and Methods). Putative triethylammonium p-tolyl H-phosphonate 11b may be prepared by evaporating a methanolic solution of crystalline ammonium p-tolyl H-phosphonate 11a (5) and triethylamine under reduced pressure. In order to avoid possible side reactions and also to facilitate purification of the products, we favour the use of 2-N-acyl-6-O-aryl-protected guanosine (6) and 2′-deoxyguanosine (7) derivatives in solution phase oligonucleotide synthesis. The 5′-O-(DMTr)-2′-O-(Fpmp)-guanosine derivative 9; B = 14 was prepared from 2-N-phenylacetyl-3′,5′-O-(1,1,3,3-tetraisopropyldisiloxan-1,3-diyl)guanosine 17 (8) in four steps and in 76% overall yield by the procedure indicated (Scheme 2b and Materials and Methods).
It was decided, in this preliminary study, to prepare the tetraribonucleoside triphosphate 18 and the cyclic tetraribonucleotide 19. The coupling procedure used in the synthesis of oligoribonucleotides was the same as that used previously (1) in oligodeoxyribonucleotide synthesis. 2′-O-(Fpmp)-3′-O-(Lev)-uridine 20 (1.0 mol equiv.), which was prepared in two steps and in 82% isolated yield from the corresponding 5′-O-(DMTr)-2′-O-(Fpmp)-derivative 9; B = 15 (Materials and Methods), and the guanosine-derived H-phosphonate building block 10; B = 14 (1.2 mol equiv.) were allowed to react (Scheme 3) with di-(2-chlorophenyl) phosphorochloridate 5 (3.0 mol equiv.) in dry pyridine/dichloromethane (9:1 v/v) solution at -40_C. After 10 min, 2-(4-methylphenyl)sulphanyl-1H-isoindole-1,3(2H)-dione 6b (9) (2.0 mol equiv.) was added and the reactants were kept at -40_C. After a further period of 15 min, the products were worked up and treated with trifluoroacetic acid to remove the 5′-O-(DMTr) protecting group. Following the chromatographic purification of the products, the partially protected dinucleoside phosphorothioate 21; B = 14 was isolated as a colourless solid in 98% overall yield for the three-step procedure. The p-tolyl 6b rather than the p-chlorophenyl sulphur transfer reagent 6a was used in this study in order to make the phosphorothioate triester intermediates (e.g. 21) even more robust. A number of years ago, we introduced (10) a system of abbreviations for protected oligoribonucleotides in which ribonucleoside residues are italicized (as in A, C and G) if their base residues are protected, and a prime is added (as in A′, C′, G′ and U′) if their 2′-hydroxy functions are protected. The protecting groups used in this study are indicated in Scheme 2. If internucleotide linkages are protected, they are also italicized. Thus, in the present study, -p(s′)-represents an S-(p-tolyl)-protected phosphorothioate internucleotide linkage (as in 21). As terminal H-phosphonate monoesters [i.e. p(H)] are not protected, they are cyclic tetramer 25 is indicated in outline in Scheme 4c. The synthetic strategy, which involved the intramolecular coupling of a 5′-H-phosphonate with a 3′-hydroxy function, was adopted as it seemed possible that, at high dilution, phosphorylation of a 5′-hydroxy function (but not of a much more hindered 3′-hydroxy function) in the presence of a relatively large excess of coupling agent 5 might compete with the desired cyclization reaction. Following the removal of the 5′-O-(DMTr) protecting group (step iii, 98% yield), the intermediate HO-A′p(s′)C′p(s′)G′p(s′)U′-Lev was converted (step iv, 96% yield) into its 5′-H-phosphonate by the above procedure (Scheme 2a). A relatively large excess each of the putative triethylammonium p-tolyl H-phosphonate 11b (∼8 mol equiv.) and pivaloyl chloride (∼10 mol equiv.) was used. The least satisfactory step (step v, 90% yield) was the removal of the 3′-O-levulinoyl group (11) ; this reaction involved the conversion of one charged species into another and could not easily be monitored by thin layer chromatography (TLC). Cyclization was Both the fully protected tetramer 23 and the fully protected cyclic tetramer 25 were unblocked by a three-step process (Scheme 5). Treatment of each substrate with E-2-nitrobenzaldoxime 7 and TMG 8 (4) in acetonitrile solution at room temperature (step i) led smoothly to the conversion of the phosphorothioate triester groups (as in 21) into standard phosphodiester internucleotide linkages and to the removal (6) of the 6-O-(2,5-dichlorophenyl) protecting group from the guanine residue. The N-acyl protecting groups were then removed from the adenine, cytosine and guanine residues by heating with concentrated aqueous ammonia at 50_C (step ii). The latter treatment also led to the removal of the 3′-O-levulinoyl group from the acyclic tetramer 23. Finally, the 2′-O-(Fpmp) protecting groups were removed from all of the ribose residues by treatment with pH 4.0 sodium acetate buffer at 40_C (step iii). This treatment also led to the removal of the 5′-O-(DMTr) protecting group from the acyclic tetramer 23. Both the tetraribonucleoside triphosphate 18 and the cyclic tetraribonucleotide 19 were isolated as their triethylammonium salts following chromatography on DEAE-Sephadex A25. The isolated yield of tetraribonucleoside triphosphate 18 was 210 A 260 units, starting from 0.025 g (∼7.7 µmol) of fully protected material 23 and the isolated yield of cyclic tetranucleotide 19 was 230 A 260 units, again starting from 0.025 g (∼8.3 µmol) of fully protected material 25.
The 31 P NMR spectra and reverse phase HPLC profiles of the fully unblocked tetraribonucleoside triphosphate 18 and the fully unblocked cyclic tetraribonucleotide 19 are illustrated in Figure 1 . It can be seen that the phosphodiester phosphorus resonance signals at ∼δ 0 in the spectrum of the cyclic tetramer 19 (Fig. 1c) are more dispersed than in the spectrum of the linear tetramer 18 (Fig. 1a) ; however, two of the resonance signals appear to be overlapping. Integration of the 1 H NMR spectra of both tetramers (Materials and Methods) confirmed that there were five protons in the region of δ 7.5-8.5 (three well-resolved singlets, each integrating for one proton, that may be assigned to the resonances of the adenine and guanine protons, and two doublets, each integrating for one proton, that may be assigned to the H-6 resonances of the uracil and cytosine residues). In both the 1 H NMR spectra, the resonance signals in the region of δ 5.4-6.1 integrated for six protons (four anomeric protons and Η-5 of the uracil and cytosine residues). The latter signals were not fully resolved. Integration of the HPLC peaks ( Fig. 1b and d) indicated that the linear and cyclic tetramers were 100 and ∼98.5% pure, respectively.
Further confirmation of the constitutions of the tetraribonucleoside triphosphate 18 and the cyclic tetraribonucleotide 19 was provided by HPLC analysis of their enzymatic digests. Both tetramers were completely converted to their constituent nucleosides by digestion first with Crotalus adamanteus snake venom phosphodiesterase and then with Escherichia coli alkaline phosphatase. The adenosine:cytidine:guanosine:uridine ratios for the digests obtained from the tetraribonucleoside triphosphate 18 and the cyclic tetraribonucleotide 19 were estimated by reverse phase HPLC to be 1.00:1.00:1.08:1.00 and 1.00:1.03:1.04:1.00, respectively. Digestion of the tetraribonucleoside triphosphate 18 with ribonuclease A gave two components with R t (programme B; Materials and Methods) ∼11.2 and 11.6 min, believed to be r(ApCp) and r(GpU), respectively; similar digestion of the cyclic tetraribonucleotide 19 also gave r(ApCp) together with another component (R t ∼10.2 min), believed to be r(GpUp). When these two digests were further digested with E.coli alkaline phosphatase, the same two components (R t ∼11.6 and 12.55 min) were obtained in each case (Fig. 2) . These digestion products were identified as r(GpU) and r(ApC), respectively, by HPLC comparison with authentic samples supplied by Sigma-Aldrich Co.
The results of these preliminary experiments clearly indicate that the H-phosphonate approach to the solution phase synthesis of oligoribonucleotides is superior to the conventional phosphotriester approach (12,13) involving aryl (particularly 2-chlorophenyl)-protected internucleotide linkages and coupling agents such as 1-(mesitylene-2-sulphonyl)-3-nitro-1,2,4-1H-triazole (MSNT). Side reactions were not detected in the present study and the yield of fully protected tetraribonucleoside triphosphate 23 obtained was significantly higher than would have been expected in a preparation of the same product by the conventional phosphotriester approach (12) . Very little work has been reported on the chemical synthesis of cyclic oligoribonucleotides. Recently, Kool and co-workers have demonstrated that their template-directed synthesis (14) is also effective in the preparation (15) of cyclic RNA sequences. However, this methodology appears to be suitable only for the synthesis of pyrimidine-rich cyclic DNA and RNA sequences in which the number of nucleotide residues falls within a limited range. The synthesis of cyclic di- (16, 17) and tetra-ribonucleotides (17) by the phosphotriester approach in solution has also been reported. However, the cyclization yields obtained were appreciably lower than the yield of the fully protected cyclic tetraribonucleotide 25 obtained in this study. Further work needs to be carried out on the present approach to examine its generality and particularly to determine whether or not there is a ring size limitation. Studies along these lines are now in progress in this laboratory.
MATERIALS AND METHODS

General procedures
1 H NMR spectra were measured at 360 MHz with a Bruker AM 360 spectrometer; tetramethylsilane was used as an internal standard. 31 P NMR spectra were measured at 145.8 MHz with the same spectrometer; 85% orthophosphoric acid was used as an external standard. Merck silica gel 60 F 254 pre-coated plates (Art 5715 and 5642), which were developed in solvent system A (CH 2 Cl 2 /MeOH 9:1 v/v), were used for TLC. High performance liquid chromatography (HPLC) was carried out on a 250 × 4.6 mm Hypersil ODS 5µ column, which was eluted with 0. . Peaks were monitored and integrated at 270 nm. Merck Kieselgel H (Art 7729 and 9385) was used for short column chromatography. The general procedure for the chromatography of fully or partially protected oligoribonucleotide phosphorothioates (below under the preparation of DMTr-A′p(s′)C′p(s′)G′p(s′)U′-Lev 23 and the preparation of the fully protected cyclic tetraribonucleoside tetraphosphorothioate 25) was as follows. A suspension of silica gel (∼10 g/g of crude product) in dichloromethane (∼50 ml) was poured into a column and the silica gel was packed. The diameter of the column was such that the height of the silica gel was ∼1-2 cm. A solution of the crude product in dichloromethane (∼10 ml) was applied to the column, which was eluted first with ethyl acetate/ petroleum ether (b.p. 40-60_C) (50:50-100:0 v/v) in order to remove non-polar impurities. The desired product was eluted with ethyl acetate/acetone (100:0-50:50 v/v). A higher proportion of acetone was required to elute more polar products. Ion exchange chromatography was carried out on a column of DEAE-Sephadex A25, which was eluted with triethylammonium bicarbonate buffer (pH 7.5, linear gradient from 0.01 to 1.00 mol/dm 3 over 1000 ml). Triethylamine, pyridine, 1-methylpyrrolidine and 4-methylmorpholine were dried by heating with calcium hydride, under reflux, and were then distilled; TMG was dried by distillation over calcium hydride under reduced pressure; dichloromethane was dried over phosphorus pentaoxide and was then distilled; diethyl ether was dried over sodium wire; toluene was dried by distillation at atmospheric pressure and then discarding the first 20% of distillate. All solvents were stored over 4 Å molecular sieves in sealed containers. Levulinic anhydride was prepared by a previously reported procedure (18) 
2′-O-[1-(2-fluorophenyl)-4-methoxypiperidin-4-yl]-3′-Olevulinoyluridine (HO-U′-Lev) 20
A solution of 5′-O-(4,4′-dimethoxytrityl)-2′-O-[1-(2-fluorophenyl)-4-methoxypiperidin-4-yl]uridine 9; B = 15 (3.77 g, 5.0 mmol), triethylamine (2.78 ml, 20 mmol) and levulinic anhydride (2.14 g, ∼10 mmol) was stirred at room temperature. After 1 h, the products were poured into saturated aqueous sodium hydrogen carbonate (50 ml) and the resulting mixture was extracted with dichloromethane (50 ml). The organic extract was dried (MgSO 4 ) and evaporated under reduced pressure. Redistilled pyrrole (3.47 ml, 50 mmol) and trifluoroacetic acid/dichloromethane (2:98 v/v, 100 ml) were added, with stirring, to the residue at room temperature. After 1 min, 4-methylmorpholine (3.30 ml, 30 mmol) was added with continued stirring. The resulting solution was washed with saturated aqueous sodium hydrogen carbonate (2 × 50 ml), dried (MgSO 4 ) and evaporated under reduced pressure. The residue was fractionated by short column chromatography on silica gel: the appropriate fractions, which were eluted with CH 2 
6-O-(2,5-dichlorophenyl)-5′-O-(4,4′-dimethoxytrityl)-2′-O-[1-(2-fluorophenyl)-4-methoxypiperidin-4-yl]-2-N-phenylacetylguanosine 9; B = 14
2-N-phenylacetyl-3′,5′-O-(1,1,3,3-tetraisopropyldisiloxan-1,3-diyl)guanosine 17 (8) (3.22 g, 5.0 mmol) and 1-(2-fluorophenyl)-4-methoxy-1,2,5,6-tetrahydropyridine 16 (19) (2.07 g, 10 mmol) were evaporated together with dry toluene (25 ml) under reduced pressure and the residue was redissolved in dichloromethane (25 ml). Trifluoroacetic acid (1.16 ml, 15 mmol) was added and the solution was stirred at room temperature for 5 h. 4-Methylmorpholine (2.20 ml, 20 mmol) was then added and the products were poured into saturated aqueous sodium hydrogen carbonate (50 ml). The layers were separated and the aqueous layer was extracted with dichloromethane (50 ml). The combined organic layers were dried (MgSO 4 ) and evaporated under reduced pressure. After it had been co-evaporated with pyridine (25 ml) under reduced pressure, the residue was redissolved in dry pyridine (25 ml). 1-Methylpyrrolidine (7) (2.60 ml, 25 mmol) and mesitylene-2-sulphonyl chloride (2.19 g, 10 mmol) were then added to the cooled (ice-water bath), stirred solution. After 10 min, 2,5-dichlorophenol (2.45 g, 15 mmol) was added and the cooled reactants were stirred for a further period of 3 h. The products were then evaporated under reduced pressure and the residue was partitioned between dichloromethane (50 ml) and saturated aqueous sodium hydrogen carbonate (50 ml). The layers were separated and the aqueous layer was back-extracted with dichloromethane (2 × 25 ml). The combined organic layers were dried (MgSO 4 ) and then evaporated. The residue was redissolved in a 1.0 mol/dm 3 solution of tetraethylammonium fluoride in acetonitrile (35 ml). After 45 min, the products were evaporated under reduced pressure and the residue was partitioned between dichloromethane (50 ml) and saturated aqueous sodium hydrogen carbonate (50 ml). The layers were separated and the aqueous layer was back-extracted with dichloromethane (2 × 25 ml). The residue was fractionated by short column chromatography on silica gel: the appropriate fractions, which were eluted with dichloromethane/methanol (99:1-98:2 v/v), were combined and evaporated to give a colourless solid (3.05 g); R f (system A) 0.63. A solution of this material (3.02 g) in pyridine (10 ml) was evaporated under reduced pressure and the residue was redissolved in dry pyridine (20 ml) at room temperature. 4,4′-Dimethoxytrityl chloride (1.63 g, 4.8 mmol) was added to the stirred solution. After 5 h, the products were poured into saturated aqueous sodium hydrogen carbonate (50 ml) and the resulting mixture was extracted with dichloromethane (2 × 50 ml). The combined organic layers were dried (MgSO 4 ) and evaporated under reduced pressure. The residue was fractionated by short column chromatography on silica gel: the appropriate fractions, which were eluted with petroleum ether (b.p. 40-60_C)/ethyl acetate (4:1-1:1 v/v), were combined and evaporated under reduced pressure to give the title compound 9; B = 14 as a colourless solid 0 mmol) was added and the mixture was dissolved in dry pyridine (20 ml). The solution was evaporated under reduced pressure and the residue was redissolved in dry pyridine (30 ml). Pivaloyl chloride (2.46 ml, 20 mmol) was added dropwise over 1 min to the cooled [industrial methylated spirits (IMS)-dry ice bath, -30_C], stirred solution. After 30 min, water (5 ml) was added and the stirred mixture was allowed to warm up to room temperature. After a further period of 1 h, the products were partitioned between dichloromethane (100 ml) and water (100 ml). The organic layer was separated, washed with 0.5 mol/dm 3 triethylammonium phosphate buffer (pH 7.0, 3 × 25 ml) and then applied to a short column of silica gel (40 g). 
Di-2-chlorophenyl phosphorochloridate 5
2-Chlorophenol (207.2 ml, 2.0 mol), phosphorus oxychloride (93.2 ml, 1.0 mol) and 1-methylimidazole (1.0 ml) were heated together at 180_C for 15 h. Distillation of the products under reduced pressure (oil pump) gave the title compound 5 (265 g, 78%) (found, M + , 335.9277; calculated for 12 
2-(4-Methylphenyl)sulphanyl-1H-isoindole-1,3(2H)-dione 6b
p-Thiocresol (26.08 g, 0.21 mol) and phthalimide (29.43 g, 0.20 mol) were dissolved in hot pyridine (80 ml) and acetonitrile (100 ml). The resulting solution was cooled to room temperature and stirred. A solution of bromine (35.2 g, 0.22 mol) in acetonitrile (100 ml) was then added dropwise over a period of 1 h. After a further period of 2 h, methanol (200 ml) was added. The products were cooled (ice-water bath) for 30 min and then filtered to give the title compound 6b as pale yellow crystals (50.1 g, 93%) [ were co-evaporated with dry pyridine (2 × 10 ml) and the residue was then redissolved in dry pyridine (9 ml). The stirred solution was cooled to -40_C (IMS-dry ice bath) and a solution of di-2-chlorophenyl phosphorochloridate 5 (1.01 g, 3.0 mmol) in dichloromethane (1 ml) was added dropwise over 5 min. After a further period of 5 min, 2-(4-methylphenyl)sulphanyl-1H-isoindole-1,3(2H)-dione 6b (0.539 g, 2.0 mmol) was added and the reactants were stirred at -40_C for 15 min. Then pyridine/water (1:1 v/v, 1 ml) was added with continuing stirring. After 5 min, the products were evaporated under reduced pressure. The residue was dissolved in dichloromethane (50 ml) and the solution was washed with saturated aqueous sodium hydrogen carbonate (3 × 25 ml). The organic layer was dried (MgSO 4 ) and evaporated under reduced pressure. After it had been co-evaporated with dry toluene (2 × 20 ml) under reduced pressure, the residue was dissolved in dichloromethane (40 ml) at room temperature and trifluoroacetic acid (0.77 ml, 10 mmol) was added. After 1 min, 4-methylmorpholine (1.65 ml, 15 mmol) was added and the reaction solution was poured into saturated aqueous sodium hydrogen carbonate (50 ml). The layers were separated and the aqueous layer was extracted with dichloromethane (2 × 50 ml). The combined organic layers were dried (MgSO 4 ) and evaporated under reduced pressure. The residue was purified by short column chromatography on silica gel (General procedures, above): the appropriate fractions, which were eluted with ethyl acetate, were combined and evaporated under reduced pressure to give HO-G′p(s′)U′-Lev 21; B = 14 as a colourless solid (1.445 g, 98%); R f 0.68 (system A); δ P [CDCl 3 ] 24.1, 25.6. Preparation of fully protected cyclic tetraribonucleoside tetraphosphorothioate 25
